Novo Nordisk reports Q3 Wednesday premarket with consensus EPS DKK4.62 and revenue DKK73.79B versus DKK74.98B. GLP-1 demand and guidance are the tape drivers here, the quarterly headline is secondary.

What happened: Novo Nordisk (NVO) is scheduled to report Q3 earnings on Wednesday, November 4th before market open, with investors watching GLP-1 sales and outlook. Key numbers: Consensus EPS estimate DKK 4.62. Consensus revenue estimate DKK 73.79B, versus DKK 74.98B in Q3 2025. Why it matters: The consensus revenue estimate sits below the prior-year Q3 figure, and the report is a focus for GLP-1 sales and outlook.

Novo Nordisk (NVO) is scheduled to report Q3 earnings on Wednesday, November 4th before market open, with investors watching GLP-1 sales and outlook.

The consensus revenue estimate sits below the prior-year Q3 figure, and the report is a focus for GLP-1 sales and outlook.